You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNifedipine
Accession NumberDB01115  (APRD00590)
TypeSmall Molecule
GroupsApproved
DescriptionNifedipine has been formulated as both a long- and short-acting 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nifedipine prevents calcium-dependent myocyte contraction and vasoconstriction. A second proposed mechanism for the drug’s vasodilatory effects involves pH-dependent inhibition of calcium influx via inhibition of smooth muscle carbonic anhydrase. Nifedipine is used to treat hypertension and chronic stable angina.
Structure
Thumb
Synonyms
4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsaeuredimethylester
Adalat
Adapine
Coracten
Nifecard
Nifecor
Nifedipine
Nifedipino
Nifedipinum
Nifedipres
Procardia
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Adalatcapsule5 mgoralBayer Inc1997-01-072005-07-27Canada
Adalat - Cap 10mgcapsule10 mgoralBayer Inc1982-12-312005-07-27Canada
Adalat Cap 10mgcapsule10 mgoralMiles Canada Inc. Pharmaceutical Division1982-12-312000-08-01Canada
Adalat Cap 5mgcapsule5 mgoralMiles Canada Inc. Pharmaceutical Division1986-12-312000-08-01Canada
Adalat Cctablet, film coated30 mg/1oralBayer Health Care Pharmaceuticals Inc.1993-04-21Not applicableUs
Adalat Cctablet, film coated60 mg/1oralBayer Health Care Pharmaceuticals Inc.1993-04-21Not applicableUs
Adalat Cctablet, film coated90 mg/1oralBayer Health Care Pharmaceuticals Inc.1993-04-21Not applicableUs
Adalat Cctablet, film coated90 mg/1oralAphena Pharma Solutions Tennessee, Llc1993-04-21Not applicableUs
Adalat Orostablet (extended-release)30 mgoralBayer IncNot applicableNot applicableCanada
Adalat Orostablet (extended-release)60 mgoralBayer IncNot applicableNot applicableCanada
Adalat Orostablet (extended-release)20 mgoralBayer IncNot applicableNot applicableCanada
Adalat P.A.10 -srt 10mgtablet (extended-release)10 mgoralBayer Inc1989-12-302005-07-27Canada
Adalat P.A.20 -srt 20mgtablet (extended-release)20 mgoralBayer Inc1997-07-182005-07-27Canada
Adalat Pa 10 Tab 10mgtablet10 mgoralMiles Canada Inc. Pharmaceutical Division1989-12-312000-08-01Canada
Adalat Pa 20tablet20 mgoralMiles Canada Inc. Pharmaceutical Division1987-12-312000-08-01Canada
Adalat XL - Srt 20mgtablet (extended-release)20 mgoralBayer Inc1998-05-05Not applicableCanada
Adalat XL - Srt 30mgtablet (extended-release)30 mgoralBayer Inc1992-12-31Not applicableCanada
Adalat XL - Srt 60mgtablet (extended-release)60 mgoralBayer Inc1992-12-31Not applicableCanada
Adalat XL Tab 30mgtablet (extended-release)30 mgoralMiles Canada Inc. Pharmaceutical Division1992-12-311996-10-02Canada
Adalat XL Tab 60mgtablet (extended-release)60 mgoralMiles Canada Inc. Pharmaceutical Division1992-12-311996-10-02Canada
Afeditab CRtablet, extended release60 mg/60mgoralRemedy Repack2010-05-13Not applicableUs
Dom-nifedipinecapsule5 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-nifedipinecapsule10 mgoralDominion PharmacalNot applicableNot applicableCanada
Gen Nifedipine Cap 10mg USPcapsule10 mgoralGenpharm Ulc1991-12-312009-08-05Canada
Mylan-nifedipine Extended Releasetablet (extended-release)60 mgoralMylan Pharmaceuticals Ulc2008-12-30Not applicableCanada
Mylan-nifedipine Extended Releasetablet (extended-release)30 mgoralMylan Pharmaceuticals Ulc2010-04-23Not applicableCanada
Nifedipinecapsule10 mg/1oralGreenstone LLC2013-03-25Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralREMEDYREPACK INC.2014-06-16Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralAlvogen, Inc.1993-04-21Not applicableUs
Nifedipinetablet, film coated, extended release90 mg/1oralREMEDYREPACK INC.2015-11-12Not applicableUs
Nifedipinecapsule5 mgoralAa Pharma Inc1989-12-31Not applicableCanada
Nifedipinetablet, film coated, extended release30 mg/1oralGreenstone LLC2010-03-31Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Nifedipinetablet, film coated, extended release90 mg/1oralAlvogen, Inc.1993-04-21Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralContract Pharmacy Services Pa2010-04-13Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralGreenstone LLC2010-03-31Not applicableUs
Nifedipinetablet, film coated, extended release90 mg/1oralPhysicians Total Care, Inc.2003-08-11Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralAlvogen, Inc.1993-04-21Not applicableUs
Nifedipinetablet, film coated, extended release90 mg/1oralGreenstone LLC2010-03-31Not applicableUs
Nifedipinecapsule10 mgoralAa Pharma Inc1988-12-31Not applicableCanada
Nifedipine 10mg - Capcapsule10 mgoralSchein Pharmaceutical Canada Inc.1996-12-311998-08-14Canada
Nifedipine 5mg - Capcapsule5 mgoralSchein Pharmaceutical Canada Inc.1995-12-311998-08-14Canada
Nifedipine Capsules 10mgcapsule10 mgoralPrempharm Inc1997-01-052005-08-05Canada
Nifedipine ERtablet (extended-release)30 mgoralSivem Pharmaceuticals Ulc2015-09-29Not applicableCanada
Nifedipine ERtablet (extended-release)60 mgoralSivem Pharmaceuticals Ulc2015-09-29Not applicableCanada
Nifedipine ERtablet (extended-release)30 mgoralPro Doc Limitee2015-01-13Not applicableCanada
Nifedipine ERtablet (extended-release)20 mgoralPro Doc LimiteeNot applicableNot applicableCanada
Nifedipine ERtablet (extended-release)60 mgoralPro Doc Limitee2015-01-13Not applicableCanada
Nifedipine Pa -10 - Srt 10mgtablet (extended-release)10 mgoralPro Doc Limitee1996-12-062009-07-23Canada
Nifedipine Pa 10 - Srt 10mgtablet (extended-release)10 mgoralSchein Pharmaceutical Canada Inc.1995-12-312004-07-26Canada
Nifedipine Pa 20 - Srt 20mgtablet (extended-release)20 mgoralSchein Pharmaceutical Canada Inc.1995-12-312004-07-26Canada
Nifedipine Pa-20 - Srt 20mgtablet (extended-release)20 mgoralPro Doc Limitee1996-12-062009-07-23Canada
Nifedipine-10 Cap 10mgcapsule10 mgoralPro Doc Limitee1988-12-312000-07-31Canada
Novo-nifedin Cap 10mgcapsule10 mgoralNovopharm Limited1987-12-312005-08-10Canada
Novo-nifedin Cap 5mgcapsule5 mgoralNovopharm Limited1993-12-312005-08-10Canada
Novo-nifedin XLtablet (extended-release)20 mgoralNovopharm LimitedNot applicableNot applicableCanada
Novo-nifedin XLtablet (extended-release)30 mgoralNovopharm LimitedNot applicableNot applicableCanada
Novo-nifedin XLtablet (extended-release)60 mgoralNovopharm LimitedNot applicableNot applicableCanada
Nu-nifed Cap 10mgcapsule10 mgoralNu Pharm Inc1990-12-312012-09-04Canada
Nu-nifedipine-PAtablet (extended-release)20 mgoralNu Pharm Inc1997-01-212012-09-04Canada
Nu-nifedipine-PA - Prolonged Action Tabtablet (extended-release)10 mgoralNu Pharm Inc1997-01-212012-09-04Canada
PMS-nifedipinecapsule5 mgoralPharmascience Inc1997-10-24Not applicableCanada
PMS-nifedipinecapsule10 mgoralPharmascience Inc1997-10-24Not applicableCanada
PMS-nifedipine ERtablet (extended-release)20 mgoralPharmascience Inc2015-07-22Not applicableCanada
PMS-nifedipine ERtablet (extended-release)60 mgoralPharmascience Inc2015-03-17Not applicableCanada
PMS-nifedipine ERtablet (extended-release)30 mgoralPharmascience Inc2015-03-17Not applicableCanada
Procardiacapsule10 mg/1oralPfizer Laboratories Div Pfizer Inc1981-12-31Not applicableUs
Procardiacapsule10 mg/1oralREMEDYREPACK INC.2013-02-25Not applicableUs
Procardia XLtablet, film coated, extended release30 mg/1oralPfizer Laboratories Div Pfizer Inc1989-09-06Not applicableUs
Procardia XLtablet, film coated, extended release60 mg/1oralPfizer Laboratories Div Pfizer Inc1989-09-06Not applicableUs
Procardia XLtablet, film coated, extended release90 mg/1oralPfizer Laboratories Div Pfizer Inc1989-09-06Not applicableUs
Procardia XLtablet, film coated, extended release30 mg/1oralCardinal Health1989-09-06Not applicableUs
Taro-nifedipine Cap 10mgcapsule10 mgoralTaro Pharmaceuticals Inc1993-12-312000-08-31Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Afeditab CRtablet, film coated, extended release30 mg/1oralAphena Pharma Solutions Tennessee, Llc2002-11-01Not applicableUs
Afeditab CRtablet, film coated, extended release30 mg/1oralCarilion Materials Management2002-11-01Not applicableUs
Afeditab CRtablet, film coated, extended release30 mg/1oralActavis Pharma, Inc.2002-11-01Not applicableUs
Afeditab CRtablet, film coated, extended release60 mg/1oralbryant ranch prepack2002-11-01Not applicableUs
Afeditab CRtablet, film coated, extended release60 mg/1oralAphena Pharma Solutions Tennessee, Llc2002-11-01Not applicableUs
Afeditab CRtablet, film coated, extended release60 mg/1oralActavis Pharma, Inc.2002-11-01Not applicableUs
Apo-nifed Pa - Srt 20mgtablet (extended-release)20 mgoralApotex Inc1995-12-31Not applicableCanada
Apo-nifed Pa - Tab 10mgtablet10 mgoralApotex Inc1995-12-31Not applicableCanada
Nifediac Cctablet, film coated, extended release30 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Nifediac Cctablet, film coated, extended release90 mg/1oralbryant ranch prepack2002-09-16Not applicableUs
Nifediac Cctablet, film coated, extended release90 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Nifedical XLtablet, film coated, extended release60 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Nifedical XLtablet, film coated, extended release60 mg/1oralCardinal Health2000-12-11Not applicableUs
Nifedical XLtablet, film coated, extended release60 mg/1oralbryant ranch prepack2000-12-11Not applicableUs
Nifedical XLtablet, film coated, extended release30 mg/1oralbryant ranch prepack2001-02-09Not applicableUs
Nifedicalxl XLtablet, film coated, extended release30 mg/1oralAidarex Pharmaceuticals LLC2001-02-09Not applicableUs
Nifedicalxl XLtablet, film coated, extended release60 mg/1oralAidarex Pharmaceuticals LLC2000-12-11Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralMylan Pharmaceuticals Inc.2010-12-20Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralSTAT Rx USA LLC2011-06-28Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralMylan Institutional Inc.2010-09-13Not applicableUs
Nifedipinecapsule, liquid filled20 mg/1oralCardinal Health1990-09-20Not applicableUs
Nifedipinetablet, extended release30 mg/1oralbryant ranch prepack2009-10-05Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralTeva Pharmaceuticals USA Inc2001-02-09Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-06-30Not applicableUs
Nifedipinetablet, extended release30 mg/1oralTWI Pharmaceuticals, Inc.2014-11-01Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralLake Erie Medical DBA Quality Care Products LLC2005-11-21Not applicableUs
Nifedipinetablet, extended release60 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralSt Marys Medical Park Pharmacy2013-05-15Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralAmerican Health Packaging2012-05-01Not applicableUs
Nifedipinetablet, extended release60 mg/1oralOceanside Pharmaceuticals2000-12-04Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralMylan Pharmaceuticals Inc.2000-03-14Not applicableUs
Nifedipinecapsule10 mg/1oralHeritage Pharmaceuticals Inc.2010-12-07Not applicableUs
Nifedipinetablet30 mg/1oralREMEDYREPACK INC.2011-10-17Not applicableUs
Nifedipinetablet, film coated, extended release90 mg/1oralREMEDYREPACK INC.2013-05-14Not applicableUs
Nifedipinecapsule, liquid filled10 mg/1oralA S Medication Solutions Llc1991-01-01Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralClinical Solutions Wholesale2005-11-21Not applicableUs
Nifedipinetablet, extended release30 mg/1oralTYA Pharmaceuticals2012-10-18Not applicableUs
Nifedipinecapsule10 mg/1oralAmerican Health Packaging2012-02-012015-12-29Us
Nifedipinetablet, film coated, extended release30 mg/1oralKremers Urban Pharmaceuticals Inc.2005-11-21Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralTeva Pharmaceuticals USA Inc2000-12-11Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralRebel Distributors Corp2005-11-21Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralCardinal Health2010-06-23Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralMylan Pharmaceuticals Inc.2010-12-20Not applicableUs
Nifedipinetablet, film coated, extended release90 mg/1oralRebel Distributors Corp2007-10-03Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-07-23Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralMylan Institutional Inc.2010-10-01Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralPd Rx Pharmaceuticals, Inc.2005-11-21Not applicableUs
Nifedipinetablet, extended release30 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2010-07-19Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralPreferred Pharmaceuticals, Inc.2015-04-23Not applicableUs
Nifedipinetablet, extended release30 mg/1oralTEVA PHARMACEUTICALS USA2012-10-18Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-06-30Not applicableUs
Nifedipinetablet, film coated, extended release90 mg/1oralAidarex Pharmaceuticals LLC2007-10-03Not applicableUs
Nifedipinecapsule, liquid filled10 mg/1oralCardinal Health2013-06-05Not applicableUs
Nifedipinecapsule, liquid filled10 mg/1oralIVC Industries, Inc. dba Inverness Medical Nutritionals Group2009-08-01Not applicableUs
Nifedipinetablet, film coated, extended release90 mg/1oralAmerican Health Packaging2012-05-01Not applicableUs
Nifedipinetablet, extended release90 mg/1oralOceanside Pharmaceuticals2002-08-16Not applicableUs
Nifedipinetablet, film coated, extended release90 mg/1oralDispensing Solutions, Inc.2007-10-03Not applicableUs
Nifedipinetablet, film coated, extended release90 mg/1oralMylan Pharmaceuticals Inc.2000-03-14Not applicableUs
Nifedipinecapsule20 mg/1oralHeritage Pharmaceuticals Inc.2010-12-07Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralREMEDYREPACK INC.2013-06-03Not applicableUs
Nifedipinecapsule, liquid filled10 mg/1oralPhysicians Total Care, Inc.2009-01-29Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralClinical Solutions Wholesale2005-11-21Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralCardinal Health2010-06-23Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralKremers Urban Pharmaceuticals Inc.2005-11-21Not applicableUs
Nifedipinecapsule, liquid filled10 mg/1oralActavis Pharma, Inc.1991-01-01Not applicableUs
Nifedipinetablet, film coated, extended release90 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-07-23Not applicableUs
Nifedipinecapsule, liquid filled10 mg/1oralAv Pak2015-07-29Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Nifedipinetablet, film coated, extended release90 mg/1oralMylan Pharmaceuticals Inc.2010-12-20Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralRebel Distributors Corp2005-11-21Not applicableUs
Nifedipinecapsule10 mg/1oralGAVIS Pharmaceuticals, LLC2009-08-11Not applicableUs
Nifedipinetablet, film coated, extended release90 mg/1oralMylan Institutional Inc.2010-08-20Not applicableUs
Nifedipinetablet, extended release60 mg/1oralInternational Laboratories, Inc.2009-08-22Not applicableUs
Nifedipinecapsule10 mg/1oralPd Rx Pharmaceuticals, Inc.2009-08-11Not applicableUs
Nifedipinetablet, extended release60 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2010-07-19Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralPreferred Pharmaceuticals, Inc.2015-04-23Not applicableUs
Nifedipinetablet, extended release60 mg/1oralTEVA PHARMACEUTICALS USA2012-11-08Not applicableUs
Nifedipinetablet, film coated, extended release90 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-06-28Not applicableUs
Nifedipinetablet, extended release30 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralCardinal Health2007-06-20Not applicableUs
Nifedipinecapsule10 mg/1oralbryant ranch prepack2009-08-11Not applicableUs
Nifedipinecapsule, liquid filled20 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralUnit Dose Services2005-11-21Not applicableUs
Nifedipinetablet, extended release60 mg/1oralPhysicians Total Care, Inc.2009-03-05Not applicableUs
Nifedipinecapsule10 mg/1oralGolden State Medical Supply, Inc.2009-08-11Not applicableUs
Nifedipinecapsule, liquid filled10 mg/1oralAmerican Health Packaging2013-06-05Not applicableUs
Nifedipinetablet, extended release90 mg/1oralTWI Pharmaceuticals, Inc.2014-11-01Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralREMEDYREPACK INC.2014-07-29Not applicableUs
Nifedipinecapsule, liquid filled20 mg/1oralAv Pak2015-07-29Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Nifedipinecapsule, liquid filled10 mg/1oralCardinal Health1991-01-08Not applicableUs
Nifedipinecapsule10 mg/1oralCarilion Materials Management2009-08-11Not applicableUs
Nifedipinetablet, film coated, extended release90 mg/1oralKremers Urban Pharmaceuticals Inc.2007-10-03Not applicableUs
Nifedipinecapsule, liquid filled20 mg/1oralActavis Pharma, Inc.1990-09-20Not applicableUs
Nifedipinecapsule, liquid filled10 mg/1oralSTAT Rx USA LLC1989-04-28Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralMylan Pharmaceuticals Inc.2000-03-14Not applicableUs
Nifedipinetablet, extended release60 mg/1oralRebel Distributors Corp2006-12-13Not applicableUs
Nifedipinetablet, extended release90 mg/1oralActavis Inc.2012-05-29Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralREMEDYREPACK INC.2013-05-14Not applicableUs
Nifedipinetablet, extended release30 mg/1oralInternational Laboratories, Inc.2009-08-21Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralClinical Solutions Wholesale2005-11-21Not applicableUs
Nifedipinetablet, extended release30 mg/1oralMc Kesson Packaging Servives A Business Unit Of Mc Kesson Corporation2011-07-01Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralPreferred Pharmaceuticals, Inc.2015-04-23Not applicableUs
Nifedipinetablet, extended release90 mg/1oralTEVA PHARMACEUTICALS USA2013-08-02Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralCardinal Health2007-11-06Not applicableUs
Nifedipinetablet, film coated, extended release60 mg/1oralUnit Dose Services2005-11-21Not applicableUs
Nifedipinetablet, extended release60 mg/1oralTWI Pharmaceuticals, Inc.2014-11-01Not applicableUs
Nifedipinetablet, extended release30 mg/1oralPhysicians Total Care, Inc.2007-07-03Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralSt Marys Medical Park Pharmacy2013-05-15Not applicableUs
Nifedipinetablet, film coated, extended release30 mg/1oralAmerican Health Packaging2012-05-01Not applicableUs
Nifedipinetablet, extended release30 mg/1oralOceanside Pharmaceuticals2012-10-18Not applicableUs
Nifedipine ERtablet, film coated, extended release90 mg/1oralAv Pak2007-10-03Not applicableUs
Nifedipine ERtablet, film coated, extended release30 mg/1oralAv Pak2005-11-21Not applicableUs
Nifedipine ERtablet, film coated, extended release60 mg/1oralAv Pak2005-11-21Not applicableUs
Nifedipine Extended Releasetablet, extended release60 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Nifedipine Extended Releasetablet, extended release30 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Nifedipine Extended Releasetablet, extended release60 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-06-22Not applicableUs
Nifedipine Extended Releasetablet, extended release30 mg/1oralPar Pharmaceutical, Inc.2007-06-22Not applicableUs
Nifedipine Extended Releasetablet, extended release90 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Nifedipine Extended Releasetablet, extended release60 mg/1oralPar Pharmaceutical, Inc.2007-06-22Not applicableUs
Nifedipine Extended Releasetablet, extended release90 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-05-29Not applicableUs
Nifedipine Extended Releasetablet, extended release30 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Nifedipine Extended Releasetablet, extended release90 mg/1oralPar Pharmaceutical, Inc.2012-05-29Not applicableUs
Nifedipine Extended-releasetablet, extended release60 mg/1oralPar Pharmaceutical, Inc.2014-04-03Not applicableUs
Nifedipine Extended-releasetablet, extended release90 mg/1oralPar Pharmaceutical, Inc.2014-04-03Not applicableUs
Nifedipine Extended-releasetablet, extended release30 mg/1oralPar Pharmaceutical, Inc.2014-04-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdapineNot Available
AfeditabNot Available
CoractenNot Available
NifecardNot Available
NifecorNot Available
NifedicalNot Available
NifedicalXLNot Available
NifedipresNot Available
Brand mixtures
NameLabellerIngredients
Adalat XL PlusBayer Inc
SaltsNot Available
Categories
UNIII9ZF7L6G2L
CAS number21829-25-4
WeightAverage: 346.3346
Monoisotopic: 346.116486318
Chemical FormulaC17H18N2O6
InChI KeyInChIKey=HYIMSNHJOBLJNT-UHFFFAOYSA-N
InChI
InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3
IUPAC Name
3,5-dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassHydropyridines
Direct ParentDihydropyridinecarboxylic acids and derivatives
Alternative Parents
Substituents
  • Nitrobenzene
  • Dihydropyridinecarboxylic acid derivative
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Vinylogous amide
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Methyl ester
  • Organic nitro compound
  • Organic nitrite
  • C-nitro compound
  • Carboxylic acid ester
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Enamine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the management of vasospastic angina, chronic stable angina, hypertension, and Raynaud's phenomenon. May be used as a first line agent for left ventricular hypertrophy and isolated systolic hypertension (long-acting agents).
PharmacodynamicsNifedipine, the prototype of the dihydropyridine class of calcium channel blockers (CCBs), is similar to other dihydropyridines including amlodipine, felodipine, isradipine, and nicardipine. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction. Similar to other DHP CCBs, nifedipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives nifedipine additional arterial selectivity. At therapeutic sub-toxic concentrations, nifedipine has little effect on cardiac myocytes and conduction cells. By blocking the calcium channels, Nifedipine inhibits the spasm of the coronary artery and dilates the systemic arteries, results in a increase of myocardial oxygen supply and a decrease in systemic blood pressure.
Mechanism of actionNifedipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through L-type calcium channels. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. The vasodilatory effects of nifedipine result in an overall decrease in blood pressure.
Related Articles
AbsorptionRapidly and fully absorbed following oral administration.
Volume of distributionNot Available
Protein binding92-98%
Metabolism

Hepatic metabolism via cytochrome P450 system. Predominantly metabolized by CYP3A4, but also by CYP1A2 and CYP2A6 isozymes.

SubstrateEnzymesProduct
Nifedipine
dehydronifedipineDetails
Route of eliminationNifedipine is extensively metabolized to highly water-soluble, inactive metabolites accounting for 60 to 80% of the dose excreted in the urine. The remainder is excreted in the feces in metabolized form, most likely as a result of biliary excretion.
Half life2 hours
ClearanceNot Available
ToxicitySymptoms of overdose include dizziness, drowsiness, nausea, severe drop in blood pressure, slurred speech, and weakness. LD50=494 mg/kg (orally in mice); LD50=1022 mg/kg (orally in rats)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Nifedipine Action PathwayDrug actionSMP00379
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9073
Blood Brain Barrier-0.9536
Caco-2 permeable+0.7853
P-glycoprotein substrateNon-substrate0.5089
P-glycoprotein inhibitor IInhibitor0.8771
P-glycoprotein inhibitor IIInhibitor0.7902
Renal organic cation transporterNon-inhibitor0.9182
CYP450 2C9 substrateNon-substrate0.7776
CYP450 2D6 substrateNon-substrate0.5726
CYP450 3A4 substrateSubstrate0.705
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.6122
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.6715
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9013
Ames testNon AMES toxic0.6973
CarcinogenicityNon-carcinogens0.5412
BiodegradationNot ready biodegradable0.9675
Rat acute toxicity2.5425 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.863
hERG inhibition (predictor II)Non-inhibitor0.903
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedoral30 mg/1
Tablet, film coatedoral60 mg/1
Tablet, film coatedoral90 mg/1
Tabletoral20 mg
Tablet (extended-release)oral30 mg
Tablet (extended-release)oral60 mg
Tablet (delayed-release); kit; tablet (extended-release)oral
Tablet, extended releaseoral60 mg/60mg
Tablet (extended-release)oral20 mg
Tabletoral10 mg
Capsuleoral10 mg/1
Capsuleoral20 mg/1
Capsule, liquid filledoral10 mg/1
Capsule, liquid filledoral20 mg/1
Tabletoral30 mg/1
Tablet, extended releaseoral30 mg/1
Tablet, extended releaseoral60 mg/1
Tablet, extended releaseoral90 mg/1
Tablet (extended-release)oral10 mg
Capsuleoral10 mg
Capsuleoral5 mg
Tablet, film coated, extended releaseoral30 mg/1
Tablet, film coated, extended releaseoral60 mg/1
Tablet, film coated, extended releaseoral90 mg/1
Prices
Unit descriptionCostUnit
Nifedipine powder15.3USD g
Procardia XL 90 mg 24 Hour tablet4.77USD tablet
Procardia xl 90 mg tablet4.58USD tablet
Procardia xl 60 mg tablet4.43USD tablet
Procardia XL 60 mg 24 Hour tablet4.13USD tablet
Adalat CC 90 mg 24 Hour tablet3.5USD tablet
Adalat cc 90 mg tablet3.37USD tablet
Adalat CC 60 mg 24 Hour tablet2.99USD tablet
Adalat cc 60 mg tablet2.87USD tablet
NIFEdipine CR Osmotic 90 mg 24 Hour tablet2.66USD tablet
Nifediac cc 90 mg tablet2.57USD tablet
Nifedipine er 90 mg tablet2.56USD tablet
Procardia xl 30 mg tablet2.56USD tablet
Procardia XL 30 mg 24 Hour tablet2.39USD tablet
NIFEdipine CR Osmotic 60 mg 24 Hour tablet2.38USD tablet
Nifedipine er 60 mg tablet2.29USD tablet
Afeditab cr 60 mg tablet2.24USD tablet
Nifediac cc 60 mg tablet2.17USD tablet
Adalat CC 30 mg 24 Hour tablet1.81USD tablet
NIFEdipine 20 mg capsule1.74USD capsule
Adalat cc 30 mg tablet1.61USD tablet
Adalat Xl 60 mg Extended-Release Tablet1.41USD tablet
NIFEdipine CR Osmotic 30 mg 24 Hour tablet1.35USD tablet
Adalat Xl 20 mg Extended-Release Tablet1.34USD tablet
Adalat Xl 30 mg Extended-Release Tablet1.34USD tablet
Nifedipine er 30 mg tablet1.32USD tablet
Afeditab cr 30 mg tablet1.26USD tablet
Mylan-Nifedipine Extended Release 60 mg Extended-Release Tablet1.18USD tablet
Procardia 10 mg capsule1.17USD capsule
Nifediac cc 30 mg tablet1.15USD tablet
NIFEdipine 10 mg capsule0.97USD capsule
Apo-Nifed 10 mg Capsule0.51USD capsule
Apo-Nifed 5 mg Capsule0.39USD capsule
Coral calcium plus 1500 mg caplet0.13USD caplet
Coral calcium 1000 mg caplet0.09USD caplet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5264446 No1993-11-232010-11-23Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point172-174 °CPhysProp
water solubilityInsolubleNot Available
logP2.20MASUMOTO,K ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0177 mg/mLALOGPS
logP2.49ALOGPS
logP1.82ChemAxon
logS-4.3ALOGPS
pKa (Strongest Basic)5.33ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.45 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity92.16 m3·mol-1ChemAxon
Polarizability33.85 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Hiroitsu Kawata, Tadayoshi Ohmura, Katsuhiko Yano, Mikio Matsumura, Saburo Higuchi, Yoshiaki Soeishi, “Nifedipine-containing solid preparation composition.” U.S. Patent US4412986, issued November, 1976.

US4412986
General References
  1. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000 Jul 29;356(9227):366-72. [PubMed:10972368 ]
  2. Poole-Wilson PA, Kirwan BA, Voko Z, de Brouwer S, van Dalen FJ, Lubsen J: Safety of nifedipine GITS in stable angina: the ACTION trial. Cardiovasc Drugs Ther. 2006 Feb;20(1):45-54. [PubMed:16552473 ]
  3. Odou P, Ferrari N, Barthelemy C, Brique S, Lhermitte M, Vincent A, Libersa C, Robert H: Grapefruit juice-nifedipine interaction: possible involvement of several mechanisms. J Clin Pharm Ther. 2005 Apr;30(2):153-8. [PubMed:15811168 ]
  4. Grossman E, Messerli FH, Grodzicki T, Kowey P: Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 1996 Oct 23-30;276(16):1328-31. [PubMed:8861992 ]
  5. Takahashi D, Oyunzul L, Onoue S, Ito Y, Uchida S, Simsek R, Gunduz MG, Safak C, Yamada S: Structure-activity relationships of receptor binding of 1,4-dihydropyridine derivatives. Biol Pharm Bull. 2008 Mar;31(3):473-9. [PubMed:18310913 ]
  6. Varon J, Marik PE: Clinical review: the management of hypertensive crises. Crit Care. 2003 Oct;7(5):374-84. Epub 2003 Jul 16. [PubMed:12974970 ]
External Links
ATC CodesC08CA05C08GA01C08CA55
AHFS Codes
  • 24:28.08
PDB EntriesNot Available
FDA labelDownload (206 KB)
MSDSDownload (74.7 KB)
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nifedipine.
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nifedipine.
AbirateroneThe serum concentration of Nifedipine can be increased when it is combined with Abiraterone.
AcebutololNifedipine may increase the hypotensive activities of Acebutolol.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nifedipine.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Nifedipine.
AcetaminophenThe serum concentration of Nifedipine can be increased when it is combined with Acetaminophen.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Nifedipine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Nifedipine.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Nifedipine.
AfatinibThe serum concentration of Nifedipine can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Nifedipine can be increased when it is combined with Albendazole.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nifedipine.
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Nifedipine.
AlectinibThe serum concentration of Nifedipine can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Nifedipine can be increased when it is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the hypotensive activities of Nifedipine.
AliskirenThe risk or severity of adverse effects can be increased when Nifedipine is combined with Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Nifedipine.
AlprenololNifedipine may increase the hypotensive activities of Alprenolol.
AmantadineThe serum concentration of Nifedipine can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Nifedipine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Nifedipine.
Aminohippuric acidThe serum concentration of Nifedipine can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Nifedipine can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Nifedipine.
AmitriptylineThe serum concentration of Nifedipine can be increased when it is combined with Amitriptyline.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nifedipine.
AmobarbitalAmobarbital may increase the hypotensive activities of Nifedipine.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Nifedipine.
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Nifedipine.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nifedipine.
AmprenavirThe serum concentration of Nifedipine can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Nifedipine can be increased when it is combined with Amsacrine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Nifedipine is combined with Amyl Nitrite.
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Nifedipine.
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Nifedipine.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Nifedipine.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Nifedipine.
AprepitantThe serum concentration of Nifedipine can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Nifedipine.
AripiprazoleAripiprazole may increase the hypotensive activities of Nifedipine.
ArotinololNifedipine may increase the hypotensive activities of Arotinolol.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Nifedipine.
ArtemetherThe metabolism of Nifedipine can be decreased when combined with Artemether.
AstemizoleThe serum concentration of Nifedipine can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Nifedipine.
AtazanavirThe serum concentration of Nifedipine can be increased when it is combined with Atazanavir.
AtenololNifedipine may increase the hypotensive activities of Atenolol.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Nifedipine.
AtomoxetineThe metabolism of Nifedipine can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Nifedipine can be increased when it is combined with Atorvastatin.
AtosibanThe risk or severity of adverse effects can be increased when Nifedipine is combined with Atosiban.
Atracurium besylateNifedipine may increase the neuromuscular blocking activities of Atracurium besylate.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Nifedipine.
AzelastineThe serum concentration of Nifedipine can be increased when it is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nifedipine is combined with Azilsartan medoxomil.
AzithromycinThe serum concentration of Nifedipine can be increased when it is combined with Azithromycin.
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nifedipine.
BarbitalBarbital may increase the hypotensive activities of Nifedipine.
BefunololNifedipine may increase the hypotensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nifedipine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nifedipine.
BenzocaineThe serum concentration of Nifedipine can be increased when it is combined with Benzocaine.
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nifedipine.
BepridilThe serum concentration of Nifedipine can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Nifedipine.
BetaxololNifedipine may increase the hypotensive activities of Betaxolol.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nifedipine.
BevantololNifedipine may increase the hypotensive activities of Bevantolol.
BexaroteneThe serum concentration of Nifedipine can be decreased when it is combined with Bexarotene.
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Nifedipine.
BiperidenThe serum concentration of Nifedipine can be increased when it is combined with Biperiden.
BisoprololNifedipine may increase the hypotensive activities of Bisoprolol.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nifedipine.
BoceprevirThe metabolism of Nifedipine can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Nifedipine.
BopindololNifedipine may increase the hypotensive activities of Bopindolol.
BortezomibThe metabolism of Nifedipine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Nifedipine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nifedipine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nifedipine.
BretyliumThe risk or severity of adverse effects can be increased when Nifedipine is combined with Bretylium.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nifedipine.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Nifedipine.
BromocriptineThe serum concentration of Nifedipine can be increased when it is combined with Bromocriptine.
BufuralolNifedipine may increase the hypotensive activities of Bufuralol.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nifedipine.
BupranololNifedipine may increase the hypotensive activities of Bupranolol.
BuprenorphineThe serum concentration of Nifedipine can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Nifedipine can be decreased when combined with Bupropion.
BuspironeThe serum concentration of Nifedipine can be increased when it is combined with Buspirone.
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Nifedipine.
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Nifedipine.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Nifedipine.
CabazitaxelThe serum concentration of Nifedipine can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Nifedipine.
CaffeineThe serum concentration of Nifedipine can be increased when it is combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Nifedipine.
CanagliflozinThe risk or severity of adverse effects can be increased when Nifedipine is combined with Canagliflozin.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Nifedipine.
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Nifedipine.
CaptoprilThe risk or severity of adverse effects can be increased when Nifedipine is combined with Captopril.
CarbamazepineThe serum concentration of Nifedipine can be decreased when it is combined with Carbamazepine.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Nifedipine.
CarteololNifedipine may increase the hypotensive activities of Carteolol.
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Nifedipine.
CarvedilolNifedipine may increase the hypotensive activities of Carvedilol.
CaspofunginThe serum concentration of Nifedipine can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Nifedipine can be decreased when combined with Celecoxib.
CeliprololNifedipine may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Nifedipine can be increased when it is combined with Ceritinib.
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Nifedipine.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Nifedipine.
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Nifedipine.
ChloroquineThe serum concentration of Nifedipine can be increased when it is combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nifedipine.
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Nifedipine.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Nifedipine.
ChlorpromazineThe serum concentration of Nifedipine can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Nifedipine can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Nifedipine can be increased when it is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nifedipine.
CholecalciferolThe metabolism of Nifedipine can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Nifedipine can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Nifedipine can be decreased when it is combined with Cholic Acid.
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Nifedipine.
CilazaprilThe risk or severity of adverse effects can be increased when Nifedipine is combined with Cilazapril.
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Nifedipine.
CinacalcetThe metabolism of Nifedipine can be decreased when combined with Cinacalcet.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Nifedipine.
CiprofloxacinThe serum concentration of Nifedipine can be increased when it is combined with Ciprofloxacin.
CisaprideThe serum concentration of Nifedipine can be increased when it is combined with Cisapride.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Nifedipine.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Nifedipine.
CitalopramThe serum concentration of Nifedipine can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Nifedipine.
ClarithromycinThe serum concentration of Nifedipine can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Nifedipine can be decreased when combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Clevidipine.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Nifedipine.
ClobazamThe metabolism of Nifedipine can be decreased when combined with Clobazam.
ClofazimineThe serum concentration of Nifedipine can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Nifedipine.
ClomipramineThe serum concentration of Nifedipine can be increased when it is combined with Clomipramine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Nifedipine.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nifedipine.
ClotrimazoleThe metabolism of Nifedipine can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Nifedipine.
ClozapineThe metabolism of Nifedipine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Nifedipine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Nifedipine.
CocaineThe metabolism of Nifedipine can be decreased when combined with Cocaine.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Nifedipine.
ColchicineThe serum concentration of Nifedipine can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Nifedipine can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Nifedipine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Nifedipine.
CrizotinibThe metabolism of Nifedipine can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Nifedipine.
CyclophosphamideThe serum concentration of Nifedipine can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Nifedipine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Nifedipine.
Cyproterone acetateThe serum concentration of Nifedipine can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Nifedipine.
DabrafenibThe serum concentration of Nifedipine can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Nifedipine can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Nifedipine.
DactinomycinThe serum concentration of Nifedipine can be increased when it is combined with Dactinomycin.
DapagliflozinThe risk or severity of adverse effects can be increased when Nifedipine is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Nifedipine.
DarifenacinThe metabolism of Nifedipine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Nifedipine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Nifedipine can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Nifedipine.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Nifedipine.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Nifedipine.
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Nifedipine.
DeferasiroxThe serum concentration of Nifedipine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Nifedipine can be decreased when combined with Delavirdine.
DesipramineThe serum concentration of Nifedipine can be increased when it is combined with Desipramine.
DesloratadineThe serum concentration of Nifedipine can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Nifedipine can be decreased when it is combined with Dexamethasone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nifedipine.
DextromethorphanThe serum concentration of Nifedipine can be increased when it is combined with Dextromethorphan.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Nifedipine.
DiclofenacThe serum concentration of Nifedipine can be increased when it is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Nifedipine is combined with Diclofenamide.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Nifedipine.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Nifedipine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nifedipine.
DigoxinThe serum concentration of Nifedipine can be decreased when it is combined with Digoxin.
DihydroergotamineThe metabolism of Nifedipine can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Nifedipine.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Nifedipine.
DinutuximabThe risk or severity of adverse effects can be increased when Nifedipine is combined with Dinutuximab.
DiphenhydramineThe metabolism of Nifedipine can be decreased when combined with Diphenhydramine.
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nifedipine.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Nifedipine.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Nifedipine.
DoxazosinDoxazosin may increase the hypotensive activities of Nifedipine.
DoxazosinThe risk or severity of adverse effects can be increased when Nifedipine is combined with Doxazosin.
DoxepinThe serum concentration of Nifedipine can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Nifedipine.
DoxycyclineThe metabolism of Nifedipine can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Nifedipine can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Nifedipine can be decreased when combined with Dronedarone.
DuloxetineNifedipine may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineThe metabolism of Nifedipine can be decreased when combined with Duloxetine.
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Nifedipine.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Nifedipine.
EfavirenzThe serum concentration of Nifedipine can be decreased when it is combined with Efavirenz.
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Nifedipine.
ElbasvirThe serum concentration of Nifedipine can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Nifedipine.
EliglustatThe metabolism of Nifedipine can be decreased when combined with Eliglustat.
EmpagliflozinThe risk or severity of adverse effects can be increased when Nifedipine is combined with Empagliflozin.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nifedipine.
EnzalutamideThe serum concentration of Nifedipine can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Nifedipine.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nifedipine.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nifedipine.
ErgonovineThe serum concentration of Nifedipine can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Nifedipine can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Nifedipine.
ErythromycinThe metabolism of Nifedipine can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Nifedipine.
Eslicarbazepine acetateThe serum concentration of Nifedipine can be decreased when it is combined with Eslicarbazepine acetate.
EsmololNifedipine may increase the hypotensive activities of Esmolol.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nifedipine.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Nifedipine.
EstramustineThe serum concentration of Nifedipine can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Nifedipine.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Nifedipine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nifedipine.
EthanolThe serum concentration of Nifedipine can be increased when it is combined with Ethanol.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Nifedipine.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Nifedipine.
EtoposideThe serum concentration of Nifedipine can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Nifedipine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nifedipine.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Nifedipine.
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Nifedipine.
FentanylThe serum concentration of Nifedipine can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nifedipine.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Nifedipine.
FexofenadineThe serum concentration of Nifedipine can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Nifedipine.
FidaxomicinThe serum concentration of Nifedipine can be increased when it is combined with Fidaxomicin.
FluconazoleThe serum concentration of Nifedipine can be increased when it is combined with Fluconazole.
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Nifedipine.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Nifedipine.
FlupentixolThe serum concentration of Nifedipine can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Nifedipine can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Nifedipine can be increased when it is combined with Flurazepam.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Nifedipine.
FluvoxamineThe metabolism of Nifedipine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Nifedipine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Nifedipine can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nifedipine.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nifedipine.
FosphenytoinThe serum concentration of Nifedipine can be decreased when it is combined with Fosphenytoin.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Nifedipine.
Fusidic AcidThe serum concentration of Nifedipine can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Nifedipine.
GefitinibThe serum concentration of Nifedipine can be increased when it is combined with Gefitinib.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Nifedipine.
GenisteinThe serum concentration of Nifedipine can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Nifedipine can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Nifedipine can be increased when it is combined with Glycerol.
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Nifedipine.
Gramicidin DThe serum concentration of Nifedipine can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Nifedipine.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Nifedipine.
GrepafloxacinThe serum concentration of Nifedipine can be increased when it is combined with Grepafloxacin.
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Nifedipine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nifedipine.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Nifedipine.
HaloperidolThe serum concentration of Nifedipine can be increased when it is combined with Haloperidol.
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nifedipine.
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Nifedipine.
HexobarbitalHexobarbital may increase the hypotensive activities of Nifedipine.
HydralazineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Hydralazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nifedipine.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Nifedipine.
HydrocortisoneThe serum concentration of Nifedipine can be increased when it is combined with Hydrocortisone.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Nifedipine.
IdelalisibThe serum concentration of Nifedipine can be increased when it is combined with Idelalisib.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Nifedipine.
ImatinibThe metabolism of Nifedipine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Nifedipine.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Nifedipine.
ImipramineThe serum concentration of Nifedipine can be increased when it is combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Nifedipine.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Nifedipine.
IndenololNifedipine may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Nifedipine can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Nifedipine.
IndomethacinThe serum concentration of Nifedipine can be increased when it is combined with Indomethacin.
IndoraminIndoramin may increase the hypotensive activities of Nifedipine.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nifedipine.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Nifedipine.
IsavuconazoniumThe metabolism of Nifedipine can be decreased when combined with Isavuconazonium.
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Nifedipine.
IsoniazidThe metabolism of Nifedipine can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nifedipine.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nifedipine.
IsoxsuprineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Nifedipine.
ItraconazoleThe serum concentration of Nifedipine can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Nifedipine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Nifedipine.
IvermectinThe serum concentration of Nifedipine can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Nifedipine can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Nifedipine.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Nifedipine.
KetoconazoleThe serum concentration of Nifedipine can be increased when it is combined with Ketoconazole.
LabetalolNifedipine may increase the hypotensive activities of Labetalol.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Nifedipine.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Nifedipine.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Nifedipine.
LansoprazoleThe serum concentration of Nifedipine can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Nifedipine can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Nifedipine.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Nifedipine.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Nifedipine.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Nifedipine.
LevobunololNifedipine may increase the hypotensive activities of Levobunolol.
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Nifedipine.
LevodopaNifedipine may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Nifedipine.
LevofloxacinThe serum concentration of Nifedipine can be increased when it is combined with Levofloxacin.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Nifedipine.
LevothyroxineThe serum concentration of Nifedipine can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Nifedipine can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Nifedipine.
LiothyronineThe serum concentration of Nifedipine can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Nifedipine can be decreased when it is combined with Liotrix.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nifedipine.
LomitapideThe serum concentration of Nifedipine can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Nifedipine.
LoperamideThe serum concentration of Nifedipine can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Nifedipine can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Nifedipine can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Nifedipine can be decreased when combined with Lorcaserin.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nifedipine.
LovastatinThe metabolism of Nifedipine can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Nifedipine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Nifedipine can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Nifedipine can be decreased when combined with Lumefantrine.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Nifedipine is combined with Magnesium hydroxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Nifedipine is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Nifedipine is combined with Magnesium salicylate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nifedipine is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Nifedipine.
MaprotilineThe serum concentration of Nifedipine can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Nifedipine can be increased when it is combined with Mebendazole.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nifedipine.
MefloquineThe serum concentration of Nifedipine can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Nifedipine can be increased when it is combined with Megestrol acetate.
MeprobamateThe serum concentration of Nifedipine can be increased when it is combined with Meprobamate.
MethadoneThe serum concentration of Nifedipine can be increased when it is combined with Methadone.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Nifedipine.
MethohexitalMethohexital may increase the hypotensive activities of Nifedipine.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Nifedipine.
MethotrimeprazineThe metabolism of Nifedipine can be decreased when combined with Methotrimeprazine.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nifedipine.
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Nifedipine.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nifedipine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Nifedipine.
MetipranololNifedipine may increase the hypotensive activities of Metipranolol.
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Nifedipine.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Nifedipine.
MetoprololNifedipine may increase the hypotensive activities of Metoprolol.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nifedipine.
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nifedipine.
MexiletineThe metabolism of Nifedipine can be decreased when combined with Mexiletine.
MibefradilThe serum concentration of Nifedipine can be increased when it is combined with Mibefradil.
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Nifedipine.
MiconazoleThe serum concentration of Nifedipine can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Nifedipine.
MifepristoneThe metabolism of Nifedipine can be decreased when combined with Mifepristone.
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Nifedipine.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nifedipine.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Nifedipine.
MirabegronThe metabolism of Nifedipine can be decreased when combined with Mirabegron.
MitomycinThe serum concentration of Nifedipine can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Nifedipine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Nifedipine.
MivacuriumNifedipine may increase the neuromuscular blocking activities of Mivacurium.
ModafinilThe serum concentration of Nifedipine can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Nifedipine.
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Nifedipine.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Nifedipine.
MorphineThe serum concentration of Nifedipine can be increased when it is combined with Morphine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Nifedipine.
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Nifedipine.
NadololNifedipine may increase the hypotensive activities of Nadolol.
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Nifedipine.
NafcillinThe serum concentration of Nifedipine can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nifedipine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nifedipine.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Nifedipine.
NaltrexoneThe serum concentration of Nifedipine can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Nifedipine can be increased when it is combined with Naringenin.
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Nifedipine.
NebivololThe risk or severity of adverse effects can be increased when Nifedipine is combined with Nebivolol.
NefazodoneThe serum concentration of Nifedipine can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Nifedipine can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Nifedipine can be increased when it is combined with Neostigmine.
NesiritideThe risk or severity of adverse effects can be increased when Nifedipine is combined with Nesiritide.
NetupitantThe serum concentration of Nifedipine can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Nifedipine can be decreased when it is combined with Nevirapine.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nifedipine.
NicorandilNicorandil may increase the hypotensive activities of Nifedipine.
NicotineThe metabolism of Nifedipine can be decreased when combined with Nicotine.
NilotinibThe metabolism of Nifedipine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Nifedipine.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nifedipine.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Nifedipine.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nifedipine.
NitrazepamThe serum concentration of Nifedipine can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Nifedipine can be increased when it is combined with Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nifedipine.
NitroprussideNifedipine may increase the hypotensive activities of Nitroprusside.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Nifedipine.
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Nifedipine.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Nifedipine.
NorethisteroneThe serum concentration of Nifedipine can be decreased when it is combined with Norethisterone.
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Nifedipine.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Nifedipine.
OlaparibThe metabolism of Nifedipine can be decreased when combined with Olaparib.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nifedipine.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Nifedipine.
OmeprazoleThe serum concentration of Nifedipine can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Nifedipine can be increased when it is combined with Osimertinib.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Nifedipine.
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nifedipine.
OxprenololNifedipine may increase the hypotensive activities of Oxprenolol.
P-NitrophenolThe serum concentration of Nifedipine can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Nifedipine.
PaclitaxelThe serum concentration of Nifedipine can be increased when it is combined with Paclitaxel.
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Nifedipine.
PalbociclibThe serum concentration of Nifedipine can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Nifedipine can be increased when it is combined with Palmitic Acid.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Nifedipine.
PanobinostatThe metabolism of Nifedipine can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Nifedipine can be increased when it is combined with Pantoprazole.
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Nifedipine.
ParoxetineThe serum concentration of Nifedipine can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nifedipine.
Peginterferon alfa-2bThe serum concentration of Nifedipine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololNifedipine may increase the hypotensive activities of Penbutolol.
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Nifedipine.
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nifedipine.
PentobarbitalThe serum concentration of Nifedipine can be decreased when it is combined with Pentobarbital.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Nifedipine.
PhenobarbitalThe serum concentration of Nifedipine can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nifedipine.
PhenytoinThe serum concentration of Nifedipine can be decreased when it is combined with Phenytoin.
PimozideThe serum concentration of Nifedipine can be increased when it is combined with Pimozide.
PindololNifedipine may increase the hypotensive activities of Pindolol.
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Nifedipine.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Nifedipine.
Platelet Activating FactorThe serum concentration of Nifedipine can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Nifedipine.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Nifedipine.
PonatinibThe serum concentration of Nifedipine can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Nifedipine can be increased when it is combined with Posaconazole.
PractololNifedipine may increase the hypotensive activities of Practolol.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Nifedipine.
PravastatinThe serum concentration of Nifedipine can be increased when it is combined with Pravastatin.
PrazosinPrazosin may increase the hypotensive activities of Nifedipine.
PrazosinThe risk or severity of adverse effects can be increased when Nifedipine is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Nifedipine.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Nifedipine.
PrednisoneThe serum concentration of Nifedipine can be increased when it is combined with Prednisone.
PrimidoneThe serum concentration of Nifedipine can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Nifedipine can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Nifedipine.
PromazineThe metabolism of Nifedipine can be decreased when combined with Promazine.
PromethazineThe serum concentration of Nifedipine can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Nifedipine can be increased when it is combined with Propafenone.
PropranololNifedipine may increase the hypotensive activities of Propranolol.
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Nifedipine.
ProtriptylineThe serum concentration of Nifedipine can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nifedipine.
QuercetinThe serum concentration of Nifedipine can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Quetiapine.
QuinacrineThe serum concentration of Nifedipine can be increased when it is combined with Quinacrine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Nifedipine.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Nifedipine.
QuinidineThe serum concentration of Nifedipine can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Nifedipine.
QuinineThe serum concentration of Nifedipine can be increased when it is combined with Quinine.
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Nifedipine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nifedipine.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Nifedipine.
RanitidineThe serum concentration of Nifedipine can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nifedipine.
RapacuroniumNifedipine may increase the neuromuscular blocking activities of Rapacuronium.
ReboxetineThe serum concentration of Nifedipine can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Nifedipine can be increased when it is combined with Regorafenib.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nifedipine.
RifabutinThe serum concentration of Nifedipine can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Nifedipine can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Nifedipine can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Nifedipine.
RilpivirineThe serum concentration of Nifedipine can be increased when it is combined with Rilpivirine.
RiociguatThe risk or severity of adverse effects can be increased when Nifedipine is combined with Riociguat.
RisperidoneNifedipine may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Nifedipine.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Nifedipine.
RolapitantThe serum concentration of Nifedipine can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Nifedipine.
RopiniroleThe metabolism of Nifedipine can be decreased when combined with Ropinirole.
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nifedipine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nifedipine.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Nifedipine.
SaquinavirThe serum concentration of Nifedipine can be decreased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Nifedipine.
ScopolamineThe serum concentration of Nifedipine can be increased when it is combined with Scopolamine.
SecobarbitalSecobarbital may increase the hypotensive activities of Nifedipine.
SelegilineThe serum concentration of Nifedipine can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Nifedipine.
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Nifedipine.
SertralineThe serum concentration of Nifedipine can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Nifedipine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nifedipine.
SilodosinSilodosin may increase the hypotensive activities of Nifedipine.
SiltuximabThe serum concentration of Nifedipine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Nifedipine can be increased when it is combined with Simeprevir.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Nifedipine.
SimvastatinThe serum concentration of Nifedipine can be increased when it is combined with Simvastatin.
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Nifedipine.
SirolimusThe serum concentration of Nifedipine can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Nifedipine.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Nifedipine.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Nifedipine.
SorafenibThe serum concentration of Nifedipine can be increased when it is combined with Sorafenib.
SotalolNifedipine may increase the hypotensive activities of Sotalol.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Nifedipine.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Nifedipine.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Nifedipine.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nifedipine.
St. John's WortThe serum concentration of Nifedipine can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Nifedipine can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Nifedipine can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Nifedipine can be decreased when it is combined with Streptozocin.
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Nifedipine.
SulfinpyrazoneThe serum concentration of Nifedipine can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Nifedipine can be decreased when combined with Sulfisoxazole.
SumatriptanThe serum concentration of Nifedipine can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Nifedipine can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Nifedipine can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Nifedipine.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Nifedipine.
TamsulosinTamsulosin may increase the hypotensive activities of Nifedipine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Nifedipine.
Taurocholic AcidThe serum concentration of Nifedipine can be increased when it is combined with Taurocholic Acid.
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Nifedipine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Nifedipine.
TelaprevirThe metabolism of Nifedipine can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Nifedipine.
TelithromycinThe metabolism of Nifedipine can be decreased when combined with Telithromycin.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nifedipine.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Nifedipine.
TemsirolimusThe serum concentration of Nifedipine can be increased when it is combined with Temsirolimus.
TenofovirThe metabolism of Nifedipine can be decreased when combined with Tenofovir.
TerazosinTerazosin may increase the hypotensive activities of Nifedipine.
TerazosinThe risk or severity of adverse effects can be increased when Nifedipine is combined with Terazosin.
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Nifedipine.
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Nifedipine.
TerfenadineThe serum concentration of Nifedipine can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Nifedipine can be decreased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Nifedipine can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Nifedipine can be increased when it is combined with Testosterone.
TheophyllineThe metabolism of Nifedipine can be decreased when combined with Theophylline.
ThiamylalThiamylal may increase the hypotensive activities of Nifedipine.
ThiopentalThiopental may increase the hypotensive activities of Nifedipine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Nifedipine.
ThioridazineThe metabolism of Nifedipine can be decreased when combined with Thioridazine.
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Nifedipine.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Nifedipine.
TicagrelorThe serum concentration of Nifedipine can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Nifedipine can be decreased when combined with Ticlopidine.
TimololNifedipine may increase the hypotensive activities of Timolol.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Nifedipine.
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Nifedipine.
TipranavirThe metabolism of Nifedipine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nifedipine.
TocilizumabThe serum concentration of Nifedipine can be decreased when it is combined with Tocilizumab.
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Nifedipine.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Nifedipine.
TolvaptanThe serum concentration of Nifedipine can be increased when it is combined with Tolvaptan.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nifedipine.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Nifedipine.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Nifedipine.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nifedipine.
TranylcypromineThe metabolism of Nifedipine can be decreased when combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Nifedipine.
TrazodoneThe serum concentration of Nifedipine can be decreased when it is combined with Trazodone.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nifedipine.
TrifluoperazineThe serum concentration of Nifedipine can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Nifedipine can be increased when it is combined with Triflupromazine.
TrimazosinTrimazosin may increase the hypotensive activities of Nifedipine.
TrimethoprimThe serum concentration of Nifedipine can be decreased when it is combined with Trimethoprim.
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nifedipine.
TrimipramineThe serum concentration of Nifedipine can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Nifedipine can be increased when it is combined with Troleandomycin.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Nifedipine.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Nifedipine.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nifedipine.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Nifedipine.
VemurafenibThe serum concentration of Nifedipine can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Nifedipine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Nifedipine.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Nifedipine.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Nifedipine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Nifedipine.
VincristineThe serum concentration of Nifedipine can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Nifedipine can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Nifedipine.
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Nifedipine.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Nifedipine.
ZimelidineThe serum concentration of Nifedipine can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Nifedipine can be decreased when combined with Ziprasidone.
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Grapefruit down-regulates post-translational expression of CYP3A4, the major metabolizing enzyme of nifedipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of nifedipine and may cause toxicity. Avoid grapefruit products while on this medication.
  • Take with low fat meal.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T: The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998 Nov;125(5):1005-12. [PubMed:9846638 ]
  3. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).
Gene Name:
CACNA2D1
Uniprot ID:
P54289
Molecular Weight:
124566.93 Da
References
  1. Li GR, Deng XL, Sun H, Chung SS, Tse HF, Lau CP: Ion channels in mesenchymal stem cells from rat bone marrow. Stem Cells. 2006 Jun;24(6):1519-28. Epub 2006 Feb 16. [PubMed:16484345 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Bell DC, Butcher AJ, Berrow NS, Page KM, Brust PF, Nesterova A, Stauderman KA, Seabrook GR, Nurnberg B, Dolphin AC: Biophysical properties, pharmacology, and modulation of human, neuronal L-type (alpha(1D), Ca(V)1.3) voltage-dependent calcium currents. J Neurophysiol. 2001 Feb;85(2):816-27. [PubMed:11160515 ]
  2. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:19903818). Contributes to the regulation of the membrane potential and nerve signaling, and prevents neuronal hyperexcitability (PubMed:17156368). Forms tetrameric potassium-selective channels through which ...
Gene Name:
KCNA1
Uniprot ID:
Q09470
Molecular Weight:
56465.01 Da
References
  1. Bett GC, Rasmusson RL: Modification of K+ channel-drug interactions by ancillary subunits. J Physiol. 2008 Feb 15;586(4):929-50. Epub 2007 Dec 20. [PubMed:18096604 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1H gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1H
Uniprot ID:
O95180
Molecular Weight:
259160.2 Da
References
  1. Lee TS, Kaku T, Takebayashi S, Uchino T, Miyamoto S, Hadama T, Perez-Reyes E, Ono K: Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology. 2006;78(1):11-20. Epub 2006 Aug 7. [PubMed:16899990 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Foti RS, Rock DA, Wienkers LC, Wahlstrom JL: Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos. 2010 Jun;38(6):981-7. doi: 10.1124/dmd.110.032094. Epub 2010 Mar 4. [PubMed:20203109 ]
  2. Lee SJ, Bell DA, Coulter SJ, Ghanayem B, Goldstein JA: Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J Pharmacol Exp Ther. 2005 Apr;313(1):302-9. Epub 2005 Jan 5. [PubMed:15634941 ]
  3. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Galetin A, Clarke SE, Houston JB: Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos. 2002 Dec;30(12):1512-22. [PubMed:12433827 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Teng S, Jekerle V, Piquette-Miller M: Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos. 2003 Nov;31(11):1296-9. [PubMed:14570758 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. [PubMed:11297522 ]
  2. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001 Feb;12(4):505-13. [PubMed:11231118 ]
  3. Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW: Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603. [PubMed:11743742 ]
  4. Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65. [PubMed:12128170 ]
  5. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. [PubMed:10213372 ]
  6. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  7. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Payen L, Sparfel L, Courtois A, Vernhet L, Guillouzo A, Fardel O: The drug efflux pump MRP2: regulation of expression in physiopathological situations and by endogenous and exogenous compounds. Cell Biol Toxicol. 2002;18(4):221-33. [PubMed:12206135 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23